Welcome!

The Maryland and District of Columbia Society of Clinical Oncology, Inc. (“MDCSCO”) is committed to improving the quality and delivery of care in medical oncology in the State of Maryland and the District of Columbia. We promote appropriate standards of care in oncology and cooperate with investigators conducting cancer research.

In addition, we assist in the continuing education of oncologists and educate the public, the government, insurance carriers, and other health care providers about appropriate prevention of cancer and other therapeutic options for patients with cancer.

We encourage you to join more than 400 current members in providing the leadership in our progressive future. Click here to find out more about our membership.


Click to see the latest News & Publications

VIEWBOOK

Membership Benefits

Membership is Now FREE for
Professional
Members and for Allied
Professionals.

Click here to join!

 

IMPORTANT NOTICE TO ONCOLOGISTS

NO MORE DUES!

The Maryland and District of Columbia  Society of Clinical Oncology now offers FREE professional memberships to physician oncologists. Click here for the flyer.

As a member, you get the following benefits:

  • Free attendance at ALL MDCSCO events.
  • A legislative voice on issues of high priority to the practice of oncology.
  • Being a member of one of the U.S.'s strongest ASCO state affiliates and representation at ASCO.
  • Representation at NCCN.
  • Opportunity to be considered for elected office and other leadership roles within MDCSCO.

Confirm your membership now!

 

CMS' "Fail First" Step Therapy Policy Means Medicare Patients with Cancer Will Face More Dangerous Delays and Denials
Earlier this month, the Centers for Medicare & Medicaid Services (CMS) codified its decision to allow MA plans to use “fail first” step therapy for new starts of Part B drugs for cancer and other serious diseases. The Trump administration’s decision to finalize step therapy in MA plans means that Medicare patients with cancer will face nightmares of delays and denials while trying to access their physician-prescribed treatments

Click here for more.

MDCSCO October 24, 2018
Membership and Awards Dinner
Award Recipient Sheila Ross

UPCOMING MEETINGS

 

 
2019 - SAVE THE DATES!

(See the event calendar for more info!)

TUESDAY, June 18 - ASCO Update, Baltimore, Center Club
August 2 - Best of ASCO Reception, MDCSCO, Baltimore, MD
September 11 - Hot Topics, Annapolis, Hotel Annapolis
October 30 - MDCSCO Awards Dinner, Baltimore, Center Club
December 4 - MDCSCO Industry Spotlight, Hanover, MD - Hotel at Arundel Preserve
December 7 - 9 – ASH Annual Meeting


ANNOUNCEMENTS


Economic Cost of Cancer in U.S. Tops $94B Annually According to a Study

State-by-state variations in cancer deaths suggest that effective cancer prevention and treatment could yield economic benefits, according to a study published in JAMA Oncology.

Click here for More.

Denial Rates and Days to Pay for Cancer Drugs: Commercial Health Plan Report Card

Office-administered oncology drugs given in the community setting face stiff reimbursement challenges when billing commercial plans; while Medicare has emerged as the gold standard for both predictable payment and timeliness.

Click here for More.

Highlight Patient Horror Stories
COA recently launched a major national campaign to highlight the negative impact of pharmacy benefit managers (PBMs) on patients with cancer. The “PBM Abuses” campaign will ensure that PBM middlemen's abuse of patients with cancer is not lost in policy deliberations in Washington.

Click here for More.